[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.157.73. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1992

Treatment of Visceral Leishmaniasis

Author Affiliations

Department of Pediatrics Hematology Unit Faculty of Medicine Hacettepe University Hacettepe Children's Hospital Ankara 06100, Turkey

Am J Dis Child. 1992;146(9):1021. doi:10.1001/archpedi.1992.02160210023010
Abstract

Sir.—Mahieu and Van Acker1 reported a case of visceral leishmaniasis (kalaazar) in the November 1991 issue of AJDC. Several case reports were included in the references, but only a few were from Mediterranean countries in which the disease is more prevalent, as mentioned by the authors. I would like to bring our experience with this disease into the discussion, emphasizing treatment, since the authors pointed out persistence of marked splenomegaly in their patient at the end of treatment. Visceral leishmaniasis was diagnosed in 156 children, with ages ranging from 7 months to 8 years, between 1960 and 1987 at Hacettepe Children's Hospital, Ankara, Turkey.2,3 Twenty-three (15%) of these children were treated with only pentavalent antimony (11 received stibosamine [Neostibosan] and 12 received meglumine antimoniate [Glucantime]), and 133 (85%) were treated with meglumine antimoniate followed by pentamidine isethionate every other day, for a total of 15 doses (2.5

First Page Preview View Large
First page PDF preview
First page PDF preview
×